What is QNTM's earnings growth forecast for 2025-2025?
(NASDAQ: QNTM) Quantum Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 139.94%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 57.2%.
Quantum Biopharma's earnings in 2025 is -$14,911,480.
In 2025, QNTM is forecast to generate -$4,175,071 in earnings, with the lowest earnings forecast at -$4,175,071 and the highest earnings forecast at -$4,175,071.
What is QNTM's revenue growth forecast for 2026-2026?
(NASDAQ: QNTM) Quantum Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 0.59%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 55.6%.
Quantum Biopharma's revenue in 2025 is $0.
In 2026, QNTM is forecast to generate $40,530,721 in revenue, with the lowest revenue forecast at $40,530,721 and the highest revenue forecast at $40,530,721.
What is QNTM's forecast return on assets (ROA) for 2025-2026?
(NASDAQ: QNTM) forecast ROA is -7.66%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 12.45%.
What is QNTM's Earnings Per Share (EPS) forecast for 2025-2025?
(NASDAQ: QNTM) Quantum Biopharma's current Earnings Per Share (EPS) is -$10.83. In 2025, QNTM's EPS is forecast to hit -$1.54 (min: -$1.54, max: -$1.54).
What is QNTM's forecast return on equity (ROE) for 2025-2026?
(NASDAQ: QNTM) forecast ROE is -19.86%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.